These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 24013765

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T, Nangaku M, Yonekawa T, Okuda N, Kawamatsu S, Onoue T, Endo Y, Hara K, Cobitz AR.
    Clin J Am Soc Nephrol; 2020 Aug 07; 15(8):1155-1165. PubMed ID: 32723804
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.
    Clin J Am Soc Nephrol; 2018 Jan 06; 13(1):81-90. PubMed ID: 29097481
    [Abstract] [Full Text] [Related]

  • 6. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA, Barcia J, Benador N, Jankauskiene A, Olson K, Podracka L, Shavkin A, Srivaths P, Wong CJ, Petersen J.
    Pediatr Nephrol; 2018 Jan 06; 33(1):125-137. PubMed ID: 28815341
    [Abstract] [Full Text] [Related]

  • 7. Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan.
    Kubota M, Hiramatsu M, Yamakawa M, Fukuhara S, Morita S, Iwasaki M, Akizawa T, KRN321 SCA10 Study Group.
    Clin Exp Nephrol; 2011 Dec 06; 15(6):884-92. PubMed ID: 21898029
    [Abstract] [Full Text] [Related]

  • 8. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
    Tanaka T, Nangaku M, Imai E, Tsubakihara Y, Kamai M, Wada M, Asada S, Akizawa T.
    Clin Exp Nephrol; 2019 Feb 06; 23(2):231-243. PubMed ID: 30182223
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy, tolerability and safety of darbepoetin alfa injection for the treatment of anemia associated with chronic kidney disease (CKD) undergoing dialysis: a randomized, phase-III trial.
    Sinha SD, Bandi VK, Bheemareddy BR, Thakur P, Chary S, Mehta K, Pinnamareddy VR, Pandey R, Sreepada S, Durugkar S.
    BMC Nephrol; 2019 Mar 13; 20(1):90. PubMed ID: 30866856
    [Abstract] [Full Text] [Related]

  • 11. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M.
    J Am Soc Nephrol; 2020 Jul 13; 31(7):1628-1639. PubMed ID: 32493693
    [Abstract] [Full Text] [Related]

  • 12. Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial.
    Hayashi T, Maruyama S, Nangaku M, Narita I, Hirakata H, Tanabe K, Morita S, Tsubakihara Y, Imai E, Akizawa T, PREDICT Investigators.
    Clin J Am Soc Nephrol; 2020 May 07; 15(5):608-615. PubMed ID: 32245781
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
    Martínez Castelao A, Reyes A, Valdés F, Otero A, López de Novales E, Pallardó L, Tabernero JM, Hernández Jaras J, Lladós F.
    Nefrologia; 2003 May 07; 23(2):114-24. PubMed ID: 12778875
    [Abstract] [Full Text] [Related]

  • 15. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T.
    Ther Apher Dial; 2010 Jun 07; 14(3):240-75. PubMed ID: 20609178
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of pain and efficacy of darbepoetin alfa and epoetin Beta pegol treatment in patients receiving peritoneal dialysis.
    Otsuka T, Sakai Y, Yui S, Sukegawa M, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Tsuruoka S.
    J Nippon Med Sch; 2015 Jun 07; 82(1):21-6. PubMed ID: 25797871
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK, Cizman B, Carroll K, McMurray JJV, Perkovic V, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Stankus N, Strutz F, Blackorby A, Cobitz AR, Meadowcroft AM, Paul G, Ranganathan P, Sedani S, Solomon S.
    JAMA Intern Med; 2022 Jun 01; 182(6):592-602. PubMed ID: 35377393
    [Abstract] [Full Text] [Related]

  • 20. Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study.
    Canaud B, Mingardi G, Braun J, Aljama P, Kerr PG, Locatelli F, Villa G, Van Vlem B, McMahon AW, Kerloëguen C, Beyer U, STRIATA Study Investigators.
    Nephrol Dial Transplant; 2008 Nov 01; 23(11):3654-61. PubMed ID: 18586762
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.